This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Cabergoline was first developed in the early 1990s as a long-acting dopamine agonist to address prolactin-related disorders. It quickly gained prominence due to its extended half-life and efficacy in controlling prolactin levels. Cabergoline is classified as an ergot derivative and differs from older agents like bromocriptine due to its improved tolerability and patient compliance.
Cabergoline was approved by the U.S. Food and Drug Administration (FDA) on December 23, 1996, for the treatment of hyperprolactinemia. Since then, it has been widely used in clinical practice for various indications related to prolactin excess and dopamine receptor-related conditions.
Mechanism of Action of undefined
Cabergoline binds to dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. This binding suppresses the secretion of prolactin, thereby reducing elevated prolactin levels in conditions like hyperprolactinemia.
Uses of undefined
Cabergoline is indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. It is also used in the management of Parkinson's disease and for the inhibition of lactation.
undefined Drug administaration and Dosage available
Cabergoline is administered orally, preferably with food to reduce gastrointestinal side effects. The dosage varies based on the condition being treated:
- Hyperprolactinemia: The typical starting dose is 0.25 mg twice a week, which may be increased by 0.25 mg twice weekly increments, depending on the patient's serum prolactin levels, up to a maximum of 1 mg twice a week.
- Parkinson's Disease: Doses and schedules vary; consult a healthcare provider for individualized dosing.
Warnings, Precautions and Side Effects of undefined
Warnings
- Cardiac Valvulopathy: Cabergoline has been associated with heart valve problems. Regular monitoring through echocardiograms is recommended.
- Fibrotic Complications: There is a risk of fibrotic reactions affecting the lungs, heart, and abdomen.
- Hypotension: Cabergoline can cause orthostatic hypotension; caution is advised, especially during dose escalation.
Precautions
- Psychiatric Disorders: Use with caution in patients with a history of serious mental illness, particularly psychotic disorders.
- Hepatic Impairment: Dose adjustment may be necessary in patients with liver dysfunction.
- Pregnancy and Lactation: Cabergoline is contraindicated during lactation and should be used in pregnancy only if clearly needed.
Side Effects
Common side effects include:
- Nausea
- Headache
- Dizziness
- Fatigue
- Constipation
Serious side effects may include cardiac valvulopathy, pulmonary fibrosis, and psychiatric symptoms such as hallucinations.
Word Of Advice
Before starting cabergoline, inform your healthcare provider about any existing medical conditions, especially cardiovascular diseases, lung diseases, or psychiatric disorders. Regular monitoring of cardiac function and prolactin levels is essential during treatment. Avoid activities requiring mental alertness, such as driving or operating machinery, until you know how cabergoline affects you, as it may cause dizziness or sudden sleep onset.
Frequently Asked Question
References
Disclaimer
This information is provided for educational purposes and should not replace professional medical advice. Consult a healthcare professional for personalized recommendations.